## UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

## Nos. <u>21-3167</u>, <u>21-3168</u>, <u>21-3379</u>, <u>& 21-3380</u>

Sanofi-Aventis U.S., LLC v. United States Department of Health and Human Services Novo Nordisk Inc. v. United States Department of Health and Human Services (D.N.J. Nos. 3-21-cv-00634 & 3-21-cv-00806)

## No. <u>22-1676</u>

AstraZeneca Pharmaceuticals LP v. Secretary United States
Department of Health and Human Services
(D. Del. No. 1-21-cv-00027)

## **ORDER**

The new appeal from the above-captioned Delaware case (No. 22-1676) is hereby consolidated for disposition with the pending appeals and cross-appeals from the New Jersey cases (Nos. 21-3167, 21-3168, 21-3379, and 21-3380). The four New Jersey appeals remain further consolidated for the purposes of scheduling, the joint appendix, and the appellees' brief.

Because this Court disfavors redundant briefs, all parties are encouraged to file consolidated briefing or join in or adopt portions of other briefs by reference. <u>See</u> Fed. R. App. P. 28(i).

All case-opening forms, motions, briefs, and other documents must be filed only in the appeal(s) to which they relate.

For the Court,

<u>s/ Patricia S. Dodszuweit</u> Clerk

Dated: April 28, 2022

kr/cc: All Counsel of Record